Peptide Intelligence · peptide
MOTS-c
A mitochondrial-derived peptide proposed to influence metabolism and insulin sensitivity, based mainly on animal studies.
Approval status
Not FDA-approved
Not FDA-approved.
Compounding status
PCAC-recommended (Jul 2026) · rulemaking pending
PCAC voted Jul 23–24 2026 to recommend adding to the 503A list; non-binding, rulemaking pending.
Evidence grade
C · Animal or in-vitro only
Animal studies; a small early-phase human trial of a related analog. Minimal human data.
If you already have a vial
Products sold as research-use-only are unapproved drugs. Nothing required the seller to verify identity, purity, sterility or concentration. That is the practical risk, more than the compound itself. Worth discussing with your clinician before you continue, and worth logging so your labs can be read against it.
Known risks and label warnings
- Unknown human safety
- Effects on glucose are a reason to monitor if you use glucose-lowering medication
Interactions people ask about
- Glucose-lowering medications (theoretical)
What people often measure
Framed as things to discuss with your clinician, not a protocol.
- Fasting glucose or A1c
- Weight and body composition
Questions for your clinician
- Should my glucose be checked if I take this?
Get the full report by email
- The MOTS-c status card, monitoring list and clinician questions, printable
- The pre-therapy baseline checklist: what people commonly measure before starting any injectable
- A note the next time FDA or HHS acts on this compound
Wellness guidance only, not medical advice. We never sell or dispense medication.
Regulatory timeline for MOTS-c
2026-07-24
PCAC votes to recommend six peptides for the 503A bulks list
The Pharmacy Compounding Advisory Committee voted in favor of BPC-157, TB-500, KPV, MOTS-c, Semax and epitalon. The votes are advisory only. Until FDA completes rulemaking, none of the six is legally compoundable and research-use-only products remain unapproved drugs.
FDA PCAC meeting page2026-04-15
Federal Register notice updates the peptide 'do not compound' list
FDA published an update to the Category 2 list and opened the process for nominated peptides to be evaluated for the 503A bulks list.
Frier Levitt analysis of the Apr 15 2026 notice2026-02-27
HHS announces a review of peptide compounding policy
HHS signaled it would revisit the compounding status of several peptides, setting up the April Federal Register notice and the July advisory-committee meeting.
Frier Levitt analysis
Sources and review
Status as of 2026-09-02. Reviewed 2026-09-02 by Curtis Holder (product); clinical review pending; next review due 2026-11-01. Regulatory status changes; we update this page after each FDA or HHS action. Wellness guidance only, not medical advice. Med.xyz does not sell, prescribe or recommend any compound.